- Stocks
- Pharma & Healthcare
- Pharmaids Pharm
Pharmaids Pharm share price
NSE: PHARMAIDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Pharmaids Pharm at a glance
With a market capitalisation of ₹113 Cr, it ranks 2604th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −24.6% in FY26. Promoters held 32.99% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹113 CrRank 2604 on NSE
- Price to book
- 2.05×FY26
- ROE
- −24.6%FY26
- ROCE
- −24.2%FY26
- Debt to equity
- 0.44FY26
- Net profit margin
- −41.5%FY26
- Book value / share
- ₹13.51FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Pharmaids Pharm financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹4 Cr | ₹0 Cr | ₹15 Cr | ₹19 Cr | — |
| Operating profit | ₹0 Cr | −₹10 Cr | −₹16 Cr | −₹17 Cr | — |
| Net profit | ₹0 Cr | −₹8 Cr | −₹12 Cr | −₹14 Cr | — |
| EPS (₹) | ₹0.00 | −₹6.00 | −₹4.00 | −₹3.00 | — |
| Cash from operations | −₹0 Cr | −₹4 Cr | −₹11 Cr | −₹14 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹4 Cr | ₹30 Cr | ₹12 Cr |
| Shareholders' equity | ₹9 Cr | ₹22 Cr | ₹72 Cr | ₹59 Cr | ₹48 Cr |
Pharmaids Pharm shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 5.22% | 5.14% | 32.99% | 32.99% | 32.99% | 32.99% |
| Non-institutions | 94.78% | 94.86% | 67.01% | 67.01% | 67.01% | 67.01% |
Pharmaids Pharm vs peers
The listed Pharma & Healthcare companies nearest to Pharmaids Pharm by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
| MAKERSLMakers Labs | ₹209.00 | +0.05% | — | ₹123 Cr | 52.5 | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹21.72 | −2.12% | −50.2% | ₹120 Cr | 83.5 | — |
| PHARMAIDPharmaids Pharm | — | — | — | ₹113 Cr | — | — |
| ALPAAlpa Laboratories | ₹51.75 | −3.79% | −43.7% | ₹109 Cr | 7.3 | — |
Ask anything about Pharmaids Pharm
Pivot answers on the live chart with evidence you can check, and tests strategies against PHARMAID's own history. Try: “Why has PHARMAID moved over the last three months?” · “Backtest a 50-day moving-average crossover on PHARMAID over five years” · “Compare PHARMAID with PARNAXLAB on margins and valuation”
Frequently asked questions about Pharmaids Pharm
What is the market cap of Pharmaids Pharm?
Pharmaids Pharm's market capitalisation is ₹113 Cr (₹113 Cr) at the 19 Oct 2026 close, ranking 2604th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Pharmaids Pharm?
Return on equity was −24.6% in FY26 and return on capital employed was −24.2% in FY26 (consolidated figures).
Is Pharmaids Pharm a debt-free company?
No. Pharmaids Pharm's debt-to-equity ratio was 0.44 in FY26, with total debt of ₹12 Cr.
What is the shareholding pattern of Pharmaids Pharm?
As of 30 Jun 2026: promoters 32.99%, non-institutions 67.01%.
Who are Pharmaids Pharm's competitors?
The listed Pharma & Healthcare companies closest to Pharmaids Pharm by market cap are Parnax Lab, Krebs Biochemicals and Industries, Makers Labs, Godavari Drugs, BALAXI PHARMACEUTICALS and Alpa Laboratories.
Is Pharmaids Pharm a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Pharmaids Pharm's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PHARMAID against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text